Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Antisoma Research Limited (SRC)

  Print      Mail a friend       Annual reports

Tuesday 19 April, 2005

Antisoma Research Limited

IND granted for phase II study

AACR presentations on Antisoma's AS1404:
promising prostate and ovarian cancer data support trial plans

"US IND granted for phase II study in prostate cancer"

London, UK and American Association of Cancer Research Meeting,
Anaheim, CA, USA: 19 April 2005. Cancer drug developer Antisoma plc
(LSE:ASM) yesterday presented preclinical data showing that
combinations of its phase II drug AS1404 with the taxane drugs used
to treat prostate and ovarian cancers had significantly better
efficacy than the taxanes alone. The data support plans for
forthcoming clinical trials in these two cancers.

The US Food and Drug Administration has now approved an
'Investigational New Drug' (IND) application for a phase II study of
AS1404 in hormone-refractory prostate cancer. This study, in which
AS1404 will be combined with the taxane docetaxel, will start
shortly. A phase II study in recurrent ovarian cancer, where AS1404
will be combined with carboplatin and the taxane paclitaxel, is also
close to initiation in Europe, Australia and New Zealand. The phase
II programme began last year with a study of AS1404 with paclitaxel
in non-small cell lung cancer. Recruitment into this study is ongoing
in Australia and New Zealand, and the first efficacy findings are
expected this year.

In a further AACR presentation tomorrow, Dr Lesley McPhail of St
George's Hospital, London, UK, will show the correlation between
reduced tumour blood flow and necrosis (death) of tumours in rats
given doses of AS1404 equivalent to those currently being tested in
clinical trials.

Glyn Edwards, CEO of Antisoma, said: "The data presented at AACR show
the broad potential of AS1404 against different types of tumour and
support our plans to trial AS1404-taxane combinations in prostate and
ovarian cancers. We look forward to starting these studies and to the
first phase II results from our lung cancer trial, which we expect
during the second half of this year."

The first presentation of Antisoma's phase I trial of AS1404 (DART)
will be made at the forthcoming ASCO meeting (May 13-17, Orlando,
Florida). Also to be presented at ASCO are results from the phase I
study of Antisoma's aptamer drug AS1411 (formerly AGRO100).


Glyn Edwards, CEO, Antisoma plc +44 (0)20 8799 8200

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Buchanan Communications +44 (0)20 7466 5000

Richard Anderson

De Facto Communications +44(0)20 7940 1000 (ex-UK enquiries)

Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Background/Notes to Editors
AS1404 is a 'vascular disrupting agent' that attacks tumours by
targeting established tumour blood vessels that supply nutrients and
support further growth. Drugs in this class are distinct from
angiogenesis inhibitors, which block the growth of new tumour
vessels. AS1404 is amongst the leading small-molecule vascular
disrupting agents in clinical trials. The data presented at AACR are
consistent with many others in showing that the most effective use of
vascular disrupting agents is in combination approaches with other
cancer treatments.

Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. In 2002, Antisoma
formed a broad strategic alliance with Roche to develop and
commercialise products from Antisoma's pipeline. AS1404 is one of the
products included in this alliance. Please visit for
further information about Antisoma.